1. A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. Issue 9 (28th July 2020) Authors: Asklid, Anna; Eketorp Sylvan, Sandra; Mattsson, Agnes; Winqvist, Maria; Johansson, Hemming; Österborg, Anders; Hansson, Lotta Journal: Leukemia & lymphoma Issue: Volume 61:Issue 9(2020) Page Start: 2136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outcomes of second-line treatment in chronic lymphocytic leukemia – a population-based study from a well defined geographical region between 2003 and 2013. Issue 5 (4th May 2017) Authors: Asklid, Anna; Winqvist, Maria; Eketorp Sylvan, Sandra; Mattsson, Agnes; Björgvinsson, Einar; Søltoft, Frans; Repits, Johanna; Diels, Joris; Österborg, Anders; Hansson, Lotta Journal: Leukemia & lymphoma Issue: Volume 58:Issue 5(2017) Page Start: 1219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients. (10th August 2020) Authors: Mattsson, Agnes; Sylvan, Sandra E.; Asklid, Anna; Wiggh, Joel; Winqvist, Maria; Lundin, Jeanette; Mansouri, Larry; Rosenquist, Richard; Johansson, Hemming; Österborg, Anders; Hansson, Lotta Journal: British journal of haematology Issue: Volume 191:Number 3(2020) Page Start: 426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗